TW202337469A - 治療小細胞肺癌之方法 - Google Patents

治療小細胞肺癌之方法 Download PDF

Info

Publication number
TW202337469A
TW202337469A TW112108359A TW112108359A TW202337469A TW 202337469 A TW202337469 A TW 202337469A TW 112108359 A TW112108359 A TW 112108359A TW 112108359 A TW112108359 A TW 112108359A TW 202337469 A TW202337469 A TW 202337469A
Authority
TW
Taiwan
Prior art keywords
day
etoposide
administered
wee1 inhibitor
treatment
Prior art date
Application number
TW112108359A
Other languages
English (en)
Chinese (zh)
Inventor
伊梅迪奧 埃斯特班 羅德里戈
盧克 皮戈特
安妮 貝隆
瓦萊麗 尼可拉斯
切塞克斯 安妮 瓦斯林
拉爾斯 丹斯特魯普
克勞迪歐 贊娜
Original Assignee
瑞士商德彪製藥國際公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商德彪製藥國際公司 filed Critical 瑞士商德彪製藥國際公司
Publication of TW202337469A publication Critical patent/TW202337469A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112108359A 2022-03-07 2023-03-07 治療小細胞肺癌之方法 TW202337469A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07
EP22160556.1 2022-03-07

Publications (1)

Publication Number Publication Date
TW202337469A true TW202337469A (zh) 2023-10-01

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112108359A TW202337469A (zh) 2022-03-07 2023-03-07 治療小細胞肺癌之方法

Country Status (12)

Country Link
US (1) US20260027117A1 (https=)
EP (1) EP4489756A1 (https=)
JP (1) JP2025509278A (https=)
KR (1) KR20240158972A (https=)
CN (1) CN118843466A (https=)
AR (1) AR128711A1 (https=)
AU (1) AU2023232376A1 (https=)
CA (1) CA3253688A1 (https=)
IL (1) IL315441A (https=)
MX (1) MX2024010900A (https=)
TW (1) TW202337469A (https=)
WO (1) WO2023170065A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608940T3 (es) 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
AU2022287033B2 (en) 2021-06-04 2025-04-17 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Also Published As

Publication number Publication date
AR128711A1 (es) 2024-06-05
US20260027117A1 (en) 2026-01-29
AU2023232376A1 (en) 2024-10-10
CN118843466A (zh) 2024-10-25
KR20240158972A (ko) 2024-11-05
MX2024010900A (es) 2024-09-17
WO2023170065A1 (en) 2023-09-14
JP2025509278A (ja) 2025-04-11
CA3253688A1 (en) 2023-09-14
IL315441A (en) 2024-11-01
EP4489756A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US20240226090A1 (en) Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US12364691B2 (en) Methods for treating pancreatic cancer using combination therapies
AU2017354903A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
TW202337469A (zh) 治療小細胞肺癌之方法
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
HK40064914A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK1248608B (en) Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer
HK1209627B (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan